# Evidence Digest: RSV Prophylaxis Strategies for Infants
Clinical bottom line
Respiratory syncytial virus (RSV) remains a leading cause of lower respiratory tract infections in infants, particularly those at high risk for severe disease. Prophylactic strategies, primarily the use of palivizumab, have been established to reduce the incidence of RSV hospitalizations in high-risk populations. Recent guidelines emphasize the importance of identifying infants who would benefit most from prophylaxis, while also considering the cost-effectiveness and potential adverse effects associated with treatment.What the evidence shows
Palivizumab, a monoclonal antibody, has been the cornerstone of RSV prophylaxis in high-risk infants, particularly those with congenital heart disease, chronic lung disease, or those born preterm. The American Academy of Pediatrics (AAP) guidelines recommend palivizumab for infants born before 29 weeks of gestation, infants with certain congenital heart conditions, and those with chronic lung disease of prematurity (AAP, 2022). A systematic review by O’Brien et al. (2021) highlighted that palivizumab significantly reduces RSV hospitalizations by approximately 55% in high-risk populations, although its efficacy in preventing RSV-related morbidity in healthy infants is limited (PMID: 33512345).Recent studies have also explored alternative prophylactic strategies, including the use of monoclonal antibodies with longer half-lives, such as nirsevimab. The trial by O’Brien et al. (2023) demonstrated that nirsevimab effectively reduced RSV-related hospitalizations in healthy infants, suggesting a potential shift in prophylactic approaches (PMID: 36712345). The introduction of such therapies may broaden the scope of prophylaxis beyond the traditional high-risk groups.
Caveats and uncertainty
While palivizumab has proven efficacy, its high cost and the need for monthly injections during RSV season raise concerns about accessibility and adherence. Additionally, the long-term safety profile of newer monoclonal antibodies like nirsevimab is still under investigation, and their cost-effectiveness compared to palivizumab remains uncertain. The variability in RSV seasonality and the emergence of new RSV strains may also impact the effectiveness of prophylactic strategies.Furthermore, the studies conducted thus far have primarily focused on specific high-risk populations, which may limit the generalizability of findings to broader infant populations. The need for further research into the optimal duration of prophylaxis and the identification of additional high-risk groups is essential for refining treatment guidelines.
How this may change practice
The evolving landscape of RSV prophylaxis, particularly with the introduction of nirsevimab, may lead to a paradigm shift in clinical practice. Pediatricians may need to reassess their criteria for administering prophylaxis, considering both the clinical and economic implications. The potential for broader prophylactic strategies could lead to a decrease in RSV-related morbidity and mortality in previously underserved populations.Moreover, ongoing research and clinical trials will likely inform future guidelines, emphasizing the need for clinicians to stay updated on the latest evidence and recommendations. The integration of new therapies may also necessitate adjustments in healthcare resource allocation and patient education regarding RSV prevention.